Skip to main content

Table 2 Primary and secondary endpoints

From: Galcanezumab in episodic migraine: the phase 3, randomized, double-blind, placebo-controlled PERSIST study

Endpoint Time frame LS Mean Change (SE) LS Mean Change Difference / Odds Ratio (95% CI) p-value
Galcanezumab 120 mg Placebo
Monthly MHDs Month 1–3 -3.81 (0.23) -1.99 (0.23) -1.82 (-2.32, -1.32)a  < 0.0001
 ≥ 50% response rate Month 1–3 54.9 (2.4)b 32.9 (2.3)b 2.48 (1.87, 3.29)c  < 0.0001
MSQ-RFR Month 1–3 21.01 (0.85) 13.94 (0.88) 7.07 (5.20, 8.95)a  < 0.0001
 ≥ 75% response rate Month 1–3 29.2 (2.1)b 12.7 (1.6)b 2.82 (2.01, 3.97)c  < 0.0001
100% response rate Month 1–3 11.9 (1.4)b 3.9 (0.9)b 3.31 (1.99, 5.50)c  < 0.0001
Monthly MHDs treated with acute medication Month 1–3 -2.49 (0.22) -0.71 (0.22) -1.78 (-2.25, -1.31)a  < 0.0001
MSQ-Total Score Month 1–3 19.73 (0.81) 13.56 (0.84) 6.17 (4.39, 7.95)a  < 0.0001
MSQ-RFP Month 1–3 18.79 (0.87) 12.76 (0.90) 6.03 (4.10, 7.95)a  < 0.0001
MSQ-EF Month 1–3 17.88 (0.98) 13.72 (1.02) 4.16 (2.00, 6.32)a 0.0002
PGI-S Month 3 -0.83 (0.09) -0.61 (0.10) -0.22 (-0.43, -0.02)a 0.0284
MIDAS Total Score Month 3 -22.61 (2.96) -10.18 (3.06) -12.43 (-18.81, -6.05)a 0.0001
  1. aLS mean change difference
  2. bModel estimated rate
  3. cOdds ratio
  4. CI Confidence interval, LS Least squares, MHD Migraine headache day, MIDAS Migraine Disability Assessment, MSQ-EF Migraine Specific Quality of Life Questionnaire Emotional Function, MSQ-RFP Migraine Specific Quality of Life Questionnaire Role Function-Preventive, MSQ-RFR Migraine Specific Quality of Life Questionnaire Role Function-Restrictive, PGI-S Patient Global Impression of Severity, SE Standard error